

Appl. No. 10/027,400  
Amdt. dated August 16, 2004  
Reply to Office Action of July 16, 2004

PATENT

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

**Claim 1 (original):** A purified and isolated recombinant nucleic acid of less than about 50 kbp comprising at least about 24 contiguous nucleotides which encode a human platelet-derived growth factor receptor (hPDGF-R) polypeptide segment.

**Claim 2 (original):** A nucleic acid of Claim 1, wherein said segment is a soluble polypeptide.

**Claim 3 (original):** A nucleic acid of Claim 1, wherein said segment consists essentially of a full length extracellular region of a B type or an A type hPDGF receptor, and further has a sequence of a polypeptide in Table 2 or Table 3.

**Claim 4 (original):** A nucleic acid of Claim 1, wherein said segment comprises a phosphorylation site.

**Claim 5 (original):** A nucleic acid of Claim 1, wherein the segment is less than about 300 amino acids.

**Claim 6 (original):** A nucleic acid of Claim 1, wherein said segment is capable of binding to PDGF.

**Claim 7 (original):** A nucleic acid of Claim 1, wherein said segment is a substrate for phosphorylation.

**Claim 8 (original):** A nucleic acid of Claim 1, wherein said segment is capable of binding to a P13 kinase.

**Claim 9 (original):** A cell transformed with a nucleic acid of Claim X1, and wherein said cell is a mammalian cell.

Appl. No. 10/027,400  
Amdt. dated August 16, 2004  
Reply to Office Action of July 16, 2004

PATENT

**Claim 10 (original):** A cell of Claim 9, further comprising a glycosylation enzyme originating from a non-fungal species.

**Claim 11 (original):** A nucleic acid of Claim 1, wherein said nucleotides encoding said segment are operably linked to a promoter.

**Claim 12 (original):** A nucleic acid of Claim 1, further encoding a heterologous polypeptide which is fused to said hPDGF-R segment.

**Claim 13 (original):** A method for evaluating the ability of a compound to function as a hPDGF-R agonist or antagonist comprising the step of comparing the amount of a PDGF-induced response in a cell of Claim 9 with the response from a control cell, and wherein said PDGF-induced response is compared by measuring synthesis of DNA in a cell after contacting said cell with PDGF.

**Claim 14 (original):** A substantially pure hPDGF-R polypeptide fragment of at least about twenty amino acids having platelet-derived growth factor (PDGF) binding activity or tyrosine kinase activity.

**Claim 15 (original):** A substantially pure polypeptide fragment of Claim 14, wherein said polypeptide fragment is soluble.

**Claim 16 (original):** A hPDGF-R fragment having hPDGF-R binding activity consisting essentially of amino acids beginning at about 1 and ending at about 499 of a type B hPDGF-R, and is further derived from Table 2.

**Claim 17 (original):** A hPDGF-R fragment having hPDGF-R binding activity consisting essentially of amino acids beginning about 1 and ending at about 501 of a type A hPDGF-R, and is further derived from Table 3.

**Claim 18 (original):** A composition comprising an unglycosylated hPDGF-R fragment.

Appl. No. 10/027,400  
Amdt. dated August 16, 2004  
Reply to Office Action of July 16, 2004

PATENT

**Claim 19** (original): A composition of **Claim 18**, wherein said fragment is substantially pure.

**Claim 20** (original): A composition comprising a hPDGF-R fragment, which exhibits a glycosylation pattern which is non-fungal and non-human.

**Claim 21** (original): A composition of claim 20, wherein said fragment is essentially the extracellular region of a type B or a type A hPDGF-R.

**Claim 22** (original): A composition of **Claim 20** having a sequence from Table 2, or from Table 3.

**Claim 23** (original): A composition comprising a combination of:

- a) a recombinant nucleic acid encoding a human platelet-derived growth factor receptor polypeptide (hPDGF-R) fragment; and
- b) a non-fungal glycosylation enzyme capable of glycosylating said fragment when expressed.

**Claim 24** (original): A method for introducing a hPDGF-R activity to a cell, said method comprising the step of introducing a hPDGF-R protein fragment of at least about five hundred daltons to said cell.

**Claim 25** (original): A method for assaying the presence of a ligand for a PDGF receptor in a sample, comprising the steps of:

- combining said sample with a hPDGF receptor ligand binding site; and
- detecting binding between said ligand and said hPDGF receptor ligand binding site.

**Claim 26** (original): An isolated polypeptide of less than about 200 amino acids comprising a receptor kinase insert region.

Appl. No. 10/027,400  
Amdt. dated August 16, 2004  
Reply to Office Action of July 16, 2004

PATENT

**Claim 27** (original): An isolated polypeptide of claim 26, wherein said polypeptide has a phosphorylated amino acid residue.

**Claim 28** (original): An isolated polypeptide of claim 26, wherein said polypeptide comprises a sequence substantially homologous to a kinase insert segment of a PDGF receptor, and further has a sequence from Table 2 or Table 3.

**Claim 29** (original): An isolated polypeptide of Claim 26, with a pharmaceutically acceptable carrier.

**Claim 30** (original): A method for modulating the biological activity of a first protein which binds to a phosphorylated region of a second protein, said method comprising a step of:

adding to said first protein a peptide analogue of said phosphorylated region, wherein said analogue is capable of inhibiting the binding of said first protein to said second protein.

**Claim 31** (original): A method of selecting a molecule capable of inhibiting binding of a protein which binds to a target phosphorylated polypeptide, comprising the steps of:

contacting said protein with said target phosphorylated polypeptide in the presence of said molecule in a first analysis;

contacting said protein with said target phosphorylated polypeptide in the absence of said molecule in a second analysis; and

comparing said analyses to determine the effect of said molecule on said binding.

**Claim 32** (original): A method of Claim 31, wherein said contacting steps are performed in succession.

**Claim 33** (original): A method for modulating a P13 kinase activity comprising the step of:

Appl. No. 10/027,400  
Amdt. dated August 16, 2004  
Reply to Office Action of July 16, 2004

PATENT

adding a phosphorylated PDGF receptor kinase insert region polypeptide to said P13 kinase, thereby allowing binding between said polypeptide and said P13 kinase.

**Claim 34 (original):** A method of purifying, from a sample, a protein capable of binding to a PDGF receptor kinase insert segment, comprising the step of:

contacting said sample with an analogue of a phosphorylated polypeptide substantially homologous to a PDGF receptor kinase insert region polypeptide, thereby allowing said protein to bind specifically to said phosphorylated polypeptide.

**Claim 35 (original):** A method of isolating a nucleic acid encoding a protein capable of binding to a PDGF receptor, comprising the steps of:

combining a labeled and phosphorylated PDGF receptor kinase insert region polypeptide with cells expressing various proteins, thereby labeling those cells which express said nucleic acid to produce a protein which binds said phosphorylated polypeptide, and

isolating those cells which have been labeled.

**Claim 36 (original):** A method of Claim 35, wherein said protein capable of binding a PDGF receptor is P13 kinase or c-fms.